Axogen, Inc. (AXGN)

Market Cap	1.60B +102.2%
Revenue (ttm)	225.21M +20.2%
Net Income	-15.70M
EPS	-0.34
Shares Out	51.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,385,859
Open	31.96
Previous Close	32.50
Day's Range	30.88 - 32.45
52-Week Range	9.22 - 36.00
Beta	0.96
Analysts	Strong Buy
Price Target	35.10 (+12.43%)
Earnings Date	Feb 24, 2026

About AXGN

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Michael Dale
• Employees: 452
• Stock Exchange: NASDAQ
• Ticker Symbol: AXGN
• Website: https://www.axogeninc.com

Financial Performance

In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $35.1, which is an increase of 12.43% from the latest price.

Price Target

$35.1

(12.43% upside)

Analyst Consensus: Strong Buy